Jennewein Biotechnologie GmbH

Jennewein Biotechnologie was founded in 2005 with the vision to develop new production processes for complex oligosaccharides. In 2015, Jennewein brought its first food-grade HMO* (2‘-fucosyllactose) to the market. In November 2015, Jennewein Biotechnologie received market approval from the FDA for its first product, 2‘-fucosyllactose, for applications in infant and toddler nutrition. In summer 2016, the world’s first infant formula containing the HMO 2‘-fucosyllactose went on sale in the US.

Finally, on 25 September 2017, the European Commission voted in favor of the market approval of Jennewein’s 2‘-fucosyllactose in the European Union, 4 years after the dossier was submitted (and in the wake of that further approvals in countries such as Israel, Singapore and The Philippines have followed). Breastfeeding reduces the risk of infectious diseases in children by up to 50 %. HMOs play a major role in this process. 

Jennewein Biotechnologie is the pioneer and inventor of a unique fermentation process for the production of HMOs* identical to those present in human breast milk. Now, non-breastfed babies also have the opportunity to profit from the beneficial effects of HMOs. 

* not from human milk.

  • Ausrichtungen
    • Industrielle Prozesse
    • Lohnhersteller / Produzenten
  • Gegründet

  • Aktualisiert am